Resultado de búsqueda
Hace 5 días · About Stand Up To Cancer. Stand Up To Cancer® (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C is a 501(c)(3) charitable organization and was initially launched as a division of the Entertainment Industry Foundation.
25 de may. de 2024 · Today we are celebrating #StandUpToCancer's 16th anniversary! 🎉 Because of your donations, SU2C scientists are at the forefront of cutting-edge cancer resea...
Hace 5 días · Today, a global team of researchers funded by a Stand Up To Cancer® (SU2C) grant announced clinical trial results that point to a new immunotherapy treatment option for two of the most...
29 de may. de 2024 · As we look toward the future, SU2C President & CEO Dr. Julian Adams has set a bold goal to reduce mortality from cancer by 25% in the next five years. Learn more at StandUpToCancer.org and watch the full-length video on our YouTube channel!
15 de may. de 2024 · UChicago Medicine researchers received a grant from Stand Up To Cancer® (SU2C) in 2023 to determine if employing new methods of patient outreach — with or without engagement of a community ambassador — increase clinical trial participation among the underserved community on Chicago’s South Side.
11 de may. de 2024 · Multigene panel testing (MGPT) can identify individuals with inherited cancer risk who can benefit from early cancer surveillance and risk reduction strategies. This manuscript discusses various healthcare delivery models for MGPT including traditional in-person genetic counseling, novel integrated in-person infrastructures ...
15 de may. de 2024 · In this commentary, we advance the notion that mutant KRAS (mKRAS) is an ideal tumor neoantigen that is amenable for targeting by the adaptive immune system. Recent progress highlights key advances on various fronts that validate mKRAS as a molecular target and support further pursuit as an immunological target.
